title: Drug selection with paclitaxel restores expression of linked IL-2 receptor gamma -chain and multidrug resistance (MDR1) transgenes in canine bone marrow.
abstract: Unstable expression of transferred genes is a major obstacle to successful gene therapy of hematopoietic diseases. We have investigated in a canine large-animal model whether expression of transduced genes can be recovered in vivo. Mixed-breed dogs had undergone autologous bone marrow transplantation (BMT) with stem cell factor and granulocyte-colony-stimulating factor-mobilized retrovirally marked hematopoietic cells. The bicistronic retroviral vector construct allowed for coexpression of MDR1 and human IL-2 receptor common gamma-chain cDNAs. The latter gene is deficient in X-linked severe combined immunodeficiency. After initial high-level expression, P-glycoprotein and the gamma-chain were undetectable in blood and bone marrow 17 months post-BMT. Six months later, one dog was treated i.v. with 125 mg/m2 paclitaxel. Three administrations restored expression of the two linked genes to high levels in blood and bone marrow. Two dogs treated with higher paclitaxel doses died from myelosuppression after the first administration. As determined by flow cytometry, both genes were expressed in granulocytes, monocytes, and lymphocytes of the surviving animal. PCR analysis of DNA from peripheral blood confirmed that the retroviral cDNA was increased after paclitaxel treatment, suggesting enrichment of transduced cells. P-glycoprotein was detectable for more than 1 year after cessation of paclitaxel. Repeated analyses of blood and bone marrow aspirates gave no indication of hematopoietic disturbance after BMT with transduced cells and paclitaxel treatment. In summary, we have shown that with the use of a drug-selectable marker gene, chemotherapy can select for cells that express an otherwise nonselected therapeutic gene in blood and bone marrow.
authors.affiliation: Laboratories of Molecular Biology and Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA.
authors.forename: Thomas
authors.initials: T
authors.lastname: Licht
authors.forename: Mark
authors.initials: M
authors.lastname: Haskins
authors.forename: Paula
authors.initials: P
authors.lastname: Henthorn
authors.forename: Sandra E
authors.initials: SE
authors.lastname: Kleiman
authors.forename: David M
authors.initials: DM
authors.lastname: Bodine
authors.forename: Todd
authors.initials: T
authors.lastname: Whitwam
authors.forename: Jennifer M
authors.initials: JM
authors.lastname: Puck
authors.forename: Michael M
authors.initials: MM
authors.lastname: Gottesman
authors.forename: John R
authors.initials: JR
authors.lastname: Melniczek
mesh_terms: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1 / Q000235:genetics*; D000818:Animals; D001853:Bone Marrow / Q000378:metabolism*; D016026:Bone Marrow Transplantation; D004285:Dogs; D005260:Female; D015870:Gene Expression / Q000187:drug effects*; D006801:Humans; D017239:Paclitaxel / Q000494:pharmacology*; D015375:Receptors, Interleukin-2 / Q000235:genetics*; D019076:Transgenes
chemical_list: D020168:ATP Binding Cassette Transporter, Subfamily B, Member 1; D015375:Receptors, Interleukin-2; D017239:Paclitaxel